Shandong Jincheng Pharmaceutical Group Co., Ltd (SHE:300233)
China flag China · Delayed Price · Currency is CNY
15.12
-0.17 (-1.11%)
At close: Feb 13, 2026

SHE:300233 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
Operating Revenue
2,7703,3533,5213,4843,1272,949
Other Revenue
20.1820.1817.6621.4611.7812.55
2,7903,3733,5383,5063,1382,962
Revenue Growth (YoY)
-19.94%-4.66%0.93%11.70%5.96%5.98%
Cost of Revenue
1,7962,0702,0731,9321,5421,275
Gross Profit
994.151,3041,4651,5741,5971,687
Selling, General & Admin
686.39842.741,035996.391,1681,113
Research & Development
159.62170.34184.71171.1178.34191.91
Other Operating Expenses
27.3927.8122.532.7930.7410.32
Operating Expenses
863.171,0381,2451,2001,3731,334
Operating Income
130.98265.27219.96373.34223.97352.62
Interest Expense
-12.46-18.48-24.92-26.82-27.04-23.31
Interest & Investment Income
8.8212.915.1815.724.5412.42
Currency Exchange Gain (Loss)
7.587.581.340.97-10.1-16.02
Other Non Operating Income (Expenses)
-5.98-2.2-3.32-2.52-4.49-7.04
EBT Excluding Unusual Items
128.95265.08208.23360.66206.89318.67
Impairment of Goodwill
------741.73
Gain (Loss) on Sale of Investments
0.14-1.58-0.08-12.6-1.131.72
Gain (Loss) on Sale of Assets
1.533.37-1.981.531.180.85
Asset Writedown
-24.15-16.45-2.66-21.32-39.23-4.88
Other Unusual Items
15.6118.0221.917.728.84-
Pretax Income
122.08268.45225.41345.97196.55-425.38
Income Tax Expense
42.8560.7132.160.0973.4755.3
Earnings From Continuing Operations
79.23207.74193.31285.88123.08-480.68
Minority Interest in Earnings
-1.93-10.95-18.6-12.51-15.1-8.17
Net Income
77.3196.78174.71273.37107.98-488.84
Net Income to Common
77.3196.78174.71273.37107.98-488.84
Net Income Growth
-60.00%12.63%-36.09%153.15%--
Shares Outstanding (Basic)
391378388385386388
Shares Outstanding (Diluted)
391378388385386388
Shares Change (YoY)
3.16%-2.53%0.84%-0.17%-0.60%-0.76%
EPS (Basic)
0.200.520.450.710.28-1.26
EPS (Diluted)
0.200.520.450.710.28-1.26
EPS Growth
-61.23%15.56%-36.62%153.57%--
Free Cash Flow
174.45153.97321.18-118.0461.04273.69
Free Cash Flow Per Share
0.450.410.83-0.310.160.70
Dividend Per Share
0.2500.2500.2000.1500.1980.202
Dividend Growth
-16.67%25.00%33.33%-24.31%-1.82%0.92%
Gross Margin
35.63%38.65%41.40%44.89%50.87%56.95%
Operating Margin
4.70%7.86%6.22%10.65%7.14%11.91%
Profit Margin
2.77%5.83%4.94%7.80%3.44%-16.50%
Free Cash Flow Margin
6.25%4.56%9.08%-3.37%1.94%9.24%
EBITDA
456.34582.11525.43624.67443.16550.66
EBITDA Margin
16.36%17.26%14.85%17.82%14.12%18.59%
D&A For EBITDA
325.36316.84305.48251.33219.18198.05
EBIT
130.98265.27219.96373.34223.97352.62
EBIT Margin
4.69%7.86%6.22%10.65%7.14%11.91%
Effective Tax Rate
35.10%22.62%14.24%17.37%37.38%-
Revenue as Reported
2,7903,3733,5383,5063,1382,962
Advertising Expenses
-136.97173.31198.82--
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.